Get the Stockscreener App
1.76
0.00%
0.00
Pre-market:
1.75
-0.01
-0.57%
Aldeyra Therapeutics Inc stock is traded at $1.76, with a volume of 616.58K.
It is up +0.00% in the last 24 hours and up +4.76% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$1.76
Open:
$1.81
24h Volume:
616.58K
Relative Volume:
0.21
Market Cap:
$106.17M
Revenue:
-
Net Income/Loss:
$-27.37M
P/E Ratio:
-3.8664
EPS:
-0.4552
Net Cash Flow:
$-25.99M
1W Performance:
+1.15%
1M Performance:
+4.76%
6M Performance:
-55.89%
1Y Performance:
-36.69%
1-Day Range:
$1.74
$1.8332
1-Week Range:
$1.65
$1.8332
52-Week Range:
$1.07
$6.175
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
1.76 | 106.17M | 0 | -27.37M | -25.99M | -0.4552 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Connect - ACCESS Newswire
Aldeyra appoints Darlene Deptula-Hicks to board of directors By Investing.com - Investing.com Nigeria
Aldeyra Therapeutics (ALDX) grants director options on 73,318 shares - Stock Titan
Aldeyra Therapeutics (ALDX) director receives three new stock option grants - Stock Titan
Aldeyra Therapeutics (ALDX) director receives new stock option awards - Stock Titan
Aldeyra Therapeutics (ALDX) grants board member new stock option awards - Stock Titan
[Form 4] Aldeyra Therapeutics, Inc. Insider Trading Activity - Stock Titan
Aldeyra (ALDX) director granted multiple new stock option awards - Stock Titan
Aldeyra Therapeutics (ALDX) director receives long-dated stock option awards - Stock Titan
Aldeyra Therapeutics (ALDX) director Deptula-Hicks submits initial Form 3 - Stock Titan
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Aldeyra Therapeutics Adds Independent Director, Affirms Governance Support - The Globe and Mail
Aldeyra Therapeutics CEO, President & Director Acquires 18% More Stock - simplywall.st
CEO, President & Director of Aldeyra Therapeutics Picks Up 18% More Stock - Yahoo Finance
Darlene Deptula-Hicks joins Aldeyra (ALDX) board as audit committee chair - Stock Titan
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors - BioSpace
What Does Darlene Deptula-Hicks Bring to Aldeyra's Board - Kavout
Aldeyra appoints Darlene Deptula-Hicks to board of directors - Investing.com
Aldeyra Therapeutics eyes FDA feedback as dry eye drug faces make-or-break moment - MSN
Why Did ALDX Stock Tank 70% Today? - Stocktwits
Todd Brady Increases Stake in Aldeyra Therapeutics Inc with Sign - GuruFocus
Todd Brady Increases Stake in Aldeyra Therapeutics Inc with Significant Share Purchase - GuruFocus
Aldeyra Therapeutics CEO Todd Brady buys $418,450 in stock By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Aldeyra Therapeutics CEO Todd Brady buys $418,450 in stock - Investing.com
Aldeyra Therapeutics Insider Bought Shares Worth $418,450, According to a Recent SEC Filing - marketscreener.com
Aldeyra (NASDAQ: ALDX) CEO Todd Brady purchases 250,000 common shares - Stock Titan
3 Promising Penny Stocks With Market Caps Reaching $300M - Sahm
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment - inkl
ALDX: Late-stage dry eye program nears key FDA decision, with strong cash and AbbVie partnership - TradingView
Aldeyra Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline AdvancesCore Business Growth - newsline.com
Aldeyra Therapeutics CEO to Speak at Jefferies Global Healthcare Conference - GuruFocus
Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Business Wire
ALDX Technical Analysis | Trend, Signals & Chart Patterns | ALDEYRA THERAPEUTICS INC (NASDAQ:ALDX) - ChartMill
ALDX Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Pipeline ProgressEPS Surprise History - newsline.com
Lawsuit filed for Investors who lost money with shares of Zoetis Inc. (NYSE: ZTS) - openPR.com
ANGI Investors Have Opportunity to Join Angi Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Investor Alert: Deadline in Lawsuit on May 29, 2026 - openPR.com
Gossamer Bio, Inc. (NASDAQ: GOSS) Investor Alert: Deadline in Lawsuit on June 1, 2026 - openPR.com
Aldeyra Therapeutics Faces Class Action Deadline Amid FDA Rejections (ALDX) - GuruFocus
ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra - GuruFocus
ALDX DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Aldeyra Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
Aldeyra Therapeutics Faces Securities Fraud Lawsuit Amid FDA Rej - GuruFocus
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - 巴士的報
ALDX UPCOMING DEADLINE : The Gross Law Firm Alerts Aldeyra - GlobeNewswire
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):